Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil

Table 2 Acceptance and inclusion criteria to select patients for active surveillance protocol

Question	Items	N	%
Acceptance
Do you adopt AS in your practice for patients with low-risk and very-low risk prostate cancer?	No	22	5.3
	Yes	219	53
	Occasionally	172	41.7
Do you adopt any protocol for AS?	No	124	30.0
	John Hopkins	179	43.3
	Toronto	82	19.9
	Other	28	6.8
Inclusion criteria to select patients for AS protocol
Do you use any of the following items in your practice to define eligibility for active surveillance? *more than one answer per item was accepted
Age of the patient (years)	Not informed	91	22.0
	> 50 years	133	32.2
	> 55 years	14	3.4
	> 60 years	93	22.5
	> 70 years	71	17.2
	> 80 years	11	2.7
PSA level (ng/mL)	Not considered	27	6.5
	< 10 ng/mL	360	87.2
	Up to15 ng/mL	12	2.9
	Up to 20 ng/mL	14	3.4
PSA density (ng/mL)	Not considered	220	53.3
	< 10 ng/mL	35	8.5
	< 15 ng/mL	130	31.5
	< 20 ng/mL	28	6.8
Doubling PSA time	Not considered	164	39.7
	> 6 months	54	13.1
	> 1 year	99	24.0
	> 2 years	66	16.0
	> 3 years	20	4.8
	> 4 years	10	2.4
Clinical staging	Not considered	15	3.6
	T1	332	80.4
	T2a	48	11.6
	T2b	11	2.7
	T2c	6	1.5
	T3	1	0.2
Gleason Score in the prostate biopsy	Not considered	4	1.0
	≤ 6	385	93.2
	7 (3 + 4) only in selected cases	22	5.3
	7 (4 + 3) only in selected cases	2	0.5
Number of positive cores	Not considered	26	6.3
	≤ 2 fragments	183	44.3
	≤ 3 fragments	137	33.2
	≤ 34% of the total fragments	41	9.9
	≤ 50% of the total fragments	26	6.3
Maximum involvement of each positive core	Not considered	47	11.4
	< 20%	127	30.8
	< 30%	52	12.6
	< 50%	187	45.3
Eligibility	Not considered	83	20.1
	MRI	160	38.7
	Slide review	25	6.1
	MRI e slide review	112	27.1
	Other	33	8.0

AS active surveillance, MRI magnetic resonance imaging, PSA prostate-specific antigen

ISSN: 1471-2490